In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia1

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of leukemic B cells concomitant with immunological abnormalities and depressed immune responses. The T cell abnormalities found in CLL patients are thought to increase the risk of infection and hamper immune recognition and elimination of leukemic cells. We evaluated whether providing signals through CD3 and CD28 would correct some of these T cell defects. PBMC were incubated with anti-CD3 and anti-CD28 mAbs conjugated to superparamagnetic beads for 12–14 days. This resulted in a 1400-fold increase in T cell numbers. Activated T cells expressed high levels of CD25, CD54, CD137, and CD154, and produced IFN-γ, TNF-α, and GM-CSF. The mean T cell composition of cultures increased from ∼6% to >90% and leukemic B cells decreased from a mean of ∼85% to 0.1% or less. Leukemic B cells up-regulated expression of CD54, CD80, CD86, and CD95. Receptor up-regulation required direct cell contact with the activated T cells and could be blocked with anti-CD154 mAb, suggesting that the CD40-CD40L pathway helped mediate these effects. Poor T cell responses to allostimulation were corrected by the activation and expansion process. The skewing in the TCR repertoire returned to normal, or near normal following the culture process in eight of nine patients with abnormal TCR repertoires. Activated T cells had potent in vitro antileukemic effects in contrast to nonactivated T cells. Based upon these findings, a clinical trial has been initiated to test the potential therapeutic effects of T cells activated using this approach in patients with CLL.

[1]  E. Robinet,et al.  Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation- and transduction/selection-dependent TCR-B variable chain repertoire skewing of gene-modified cells. , 2004, Stem cells and development.

[2]  M. Connors,et al.  Immune reconstitution following autologous transfers of CD3/CD28 stimulated CD4(+) T cells to HIV-infected persons. , 2004, Clinical immunology.

[3]  Stewart Craig,et al.  Comparison of a Static Process and a Bioreactor-based Process for the GMP Manufacture of Autologous Xcellerated T Cells for Clinical Trials , 2003 .

[4]  E. Kimby,et al.  Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy , 2003, Leukemia.

[5]  S. Grupp,et al.  Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. , 2003, Blood.

[6]  R. Figlin,et al.  A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M. V. van Oers,et al.  Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia. , 2003, Blood.

[8]  Fumito Ito,et al.  Antitumor Reactivity of Anti-CD3/Anti-CD28 Bead-Activated Lymphoid Cells: Implications for Cell Therapy in a Murine Model , 2003, Journal of immunotherapy.

[9]  H. Wigzell,et al.  Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. , 2003, Blood.

[10]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[11]  T. Kipps,et al.  Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Melo,et al.  Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. , 2002, Blood.

[13]  Adrien Six,et al.  ISEApeaks: an Excel platform for GeneScan and Immunoscope data retrieval, management and analysis , 2002, Bioinform..

[14]  A. Demaine,et al.  Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B‐cell chronic lymphocytic leukaemia: evidence of immune dysregulation , 2001, British journal of haematology.

[15]  L. Rassenti,et al.  CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. , 2000, Blood.

[16]  M. Keating,et al.  Infection and immunity in chronic lymphocytic leukemia. , 2000, Mayo Clinic proceedings.

[17]  E. Robinet,et al.  Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. , 2000, Human gene therapy.

[18]  D. Hur,et al.  Role of follicular dendritic cells in the apoptosis of germinal center B cells. , 2000, Immunology letters.

[19]  X. Saulquin,et al.  The T Cell Repertoire Selected In Vitro Against EBV: Diversity, Specificity, and Improved Purification Through Early IL-2 Receptor α-Chain (CD25)-Positive Selection1 , 2000, The Journal of Immunology.

[20]  J. Ledbetter,et al.  IL-2 and IL-15 Regulate CD154 Expression on Activated CD4 T Cells1 , 2000, The Journal of Immunology.

[21]  J. Williams,et al.  Selection and expansion of T cell from untreated patients with CLL: source of cells for immune reconstitution? , 2000, Cytotherapy.

[22]  E. Read,et al.  Fas‐mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous FasL‐expressing T cells , 1999, British journal of haematology.

[23]  Y. Beguin Prediction of response to optimize outcome of treatment with erythropoietin. , 1998, Seminars in oncology.

[24]  T. Kipps,et al.  Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.

[25]  C. Katlama,et al.  Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy , 1998, Nature Medicine.

[26]  N. Kay,et al.  Impairments in immune cell function in B cell chronic lymphocytic leukemia. , 1998, Seminars in oncology.

[27]  H. Everaus,et al.  Active and indolent chronic lymphocytic leukaemia – immune and hormonal peculiarities , 1997, Cancer Immunology, Immunotherapy.

[28]  T. Kipps,et al.  Acquired CD40-ligand deficiency in chronic lymphocytic leukemia , 1997, Nature Medicine.

[29]  G. Freeman,et al.  Role of the CD40 and CD95 (APO‐1/Fas) antigens in the apoptosis of human B‐cell malignancies , 1997, British journal of haematology.

[30]  P. Tighe,et al.  Restrictions of T cell receptor beta chain repertoire in the peripheral blood of patients with systemic lupus erythematosus. , 1996, Annals of the rheumatic diseases.

[31]  M. Dougados,et al.  Spread of clonal T-cell expansions in rheumatoid arthritis patients. , 1996, Human immunology.

[32]  D. Catovsky,et al.  Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. , 1996, Leukemia.

[33]  L. Foroni,et al.  Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. , 1995, Leukemia.

[34]  P. Kourilsky,et al.  T-cell repertoire diversity and clonal expansions in normal and clinical samples. , 1995, Immunology today.

[35]  F. Orlanducci,et al.  T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. , 1994, Journal of immunology.

[36]  T. Kipps,et al.  Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.

[37]  D. Birx,et al.  Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection , 2002, Nature Medicine.